Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + paclitaxel + carboplatin + gemcitabine
- Development stage
- Discontinued
- Lead developer
- University of Michigan Rogel Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Trastuzumab + paclitaxel + carboplatin + gemcitabine is a combination chemo-immunotherapy regimen investigated for the treatment of HER2-positive advanced or metastatic urothelial carcinoma. Trastuzumab is a humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways and inducing antibody-dependent cellular cytotoxicity (ADCC). In this specific regimen, evaluated by the University of Michigan Rogel Cancer Center, trastuzumab is combined with a triplet chemotherapy backbone: paclitaxel (a microtubule-stabilizing agent), carboplatin (a DNA-alkylating platinum compound), and gemcitabine (a nucleoside analog that inhibits DNA synthesis). This multi-targeted approach was designed to exploit HER2 overexpression in a subset of bladder cancer patients while providing broad cytotoxic coverage through multiple mechanisms of action.
- Brand names
- HerceptinTaxolParaplatinGemzar
- Other names
- Trastuzumab + Chemo in Advanced Urothelial CancerTPCG regimen
02
Targets
RNR (Ribonucleotide reductase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))DNADNA polymerase family
Beyond the preview
Go deeper on trastuzumab + paclitaxel + carboplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + paclitaxel + carboplatin + gemcitabine.